论文部分内容阅读
[目的]研究Ki-67蛋白在乳腺癌组织与转移淋巴结中的表达差异及与乳腺癌预后的相关性。[方法]应用免疫组织化学技术检测180例乳腺癌组织及转移淋巴结中Ki-67蛋白的表达情况,分析其表达差异对乳腺癌患者无病生存期(DFS)和总生存期(OS)的影响。[结果]Ki-67蛋白在乳腺癌淋巴结转移灶中阳性表达率高于原发灶,两者之间差异有显著性。转移淋巴结Ki-67表达阳性组无论DFS还是OS均明显低于原发灶和淋巴结转移灶Ki-67表达均阴性组。[结论]Ki-67蛋白在乳腺癌转移淋巴结中的过度表达是评估乳腺癌预后,指导临床治疗的一个敏感的指标。
[Objective] To investigate the difference of Ki-67 expression in breast cancer tissues and metastatic lymph nodes and its correlation with the prognosis of breast cancer. [Methods] The expression of Ki-67 protein in 180 cases of breast cancer tissues and metastatic lymph nodes was detected by immunohistochemistry. The difference of expression of Ki-67 protein in disease-free survival (DFS) and overall survival (OS) of breast cancer patients was analyzed . [Results] The positive rate of Ki-67 protein in breast cancer with lymph node metastasis was higher than that in primary tumor, the difference was significant. The expression of Ki-67 in metastatic lymph nodes was significantly lower than that in both primary and metastatic lymph nodes, both in DFS and OS. [Conclusion] Overexpression of Ki-67 in metastatic lymph nodes of breast cancer is a sensitive indicator to evaluate the prognosis of breast cancer and guide the clinical treatment.